The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Antibody–drug conjugates: current status and future directions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
(1997) · PubMed · Cited by 1,541
Saito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 638
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Ducry, L., & Stump, B. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9002019 · Cited by 625
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211023109 · Cited by 596
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Dumontet, C., & Sikic, B. I. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1061 · Cited by 574
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
Strop, P., Liu, S.-H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T.-T., Ho, W.-H., Farias, S., Casas, M. G., Abdiche, Y., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.01.010 · Cited by 505
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Introducing genetically encoded aldehydes into proteins
Carrico, I. S., Carlson, B. L., & Bertozzi, C. R. (2007) · Nature Chemical Biology · doi:10.1038/nchembio878 · Cited by 438
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Katz, J., Janik, J. E., & Younes, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0488 · Cited by 368
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Kavanagh, D. O., Chambers, G., O' Grady, L., Barry, K. M., Waldron, R. P., Bennani, F., Eustace, P. W., & Tobbia, I. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-1 · Cited by 367
The Collected Papers of Paul Ehrlich
(2013) · Elsevier eBooks · doi:10.1016/c2013-0-01635-0 · Cited by 365
Beyond the Canonical 20 Amino Acids: Expanding the Genetic Lexicon
Young, T. S., & Schultz, P. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.091306 · Cited by 354
Site‐Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
Jeger, S., Zimmermann, K., Blanc, A., Grünberg, J., Honer, M., Hunziker, P., Struthers, H., & Schibli, R. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201004243 · Cited by 344
Ritchie, M., Tchistiakova, L., & Scott, N. (2013) · mAbs · doi:10.4161/mabs.22854 · Cited by 312
Sutherland, M. S. K., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510026200 · Cited by 296
Maturing antibody–drug conjugate pipeline hits 30
Mullard, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4009 · Cited by 295
Occupation and cancer of the lower urinary tract
Cole, P. T., Hoover, R. N., & Friedell, G. H. (1972) · Cancer · doi:10.1002/1097-0142(197205)29:5<1398::aid-cncr2820290542>3.0.co;2-d · Cited by 274
Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A. T., Jack, A., Junutula, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205500 · Cited by 273
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
Rabuka, D., Rush, J. S., deHart, G. W., Wu, P., & Bertozzi, C. R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.045 · Cited by 246
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Linenberger, M. L. (2005) · Leukemia · doi:10.1038/sj.leu.2403598 · Cited by 214
Moldenhauer, G., Salnikov, A. V., Lüttgau, S., Herr, I., Anderl, J., & Faulstich, H. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs140 · Cited by 199
Erickson, H. K., Lewis Phillips, G. D., Leipold, D. D., Provenzano, C. A., Mai, E., Johnson, H. A., Gunter, B., Audette, C. A., Gupta, M., Pinkas, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0727 · Cited by 194
Dubowchik, G. M., & Firestone, R. A. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00609-x · Cited by 188
Fully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
Hendriks, B. S., Opresko, L. K., Wiley, H. S., & Lauffenburger, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300477200 · Cited by 179
Collected Studies on Immunity.
(1906) · Journal of the American Medical Association · doi:10.1001/jama.1906.02520030066027 · Cited by 177
The development of pyrrolobenzodiazepines as antitumour agents
Hartley, J. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573477 · Cited by 175
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S. V., Cardillo, T. M., Hansen, H. J., Horak, I. D., Griffiths, G. L., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0204 · Cited by 167
Suppression of tumour growth in mice by a drug–antibody conjugate using a novel approach to linkage
ROWLAND, G. F., O'NEILL, G. J., & DAVIES, D. A. L. (1975) · Nature · doi:10.1038/255487a0 · Cited by 166
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., & Lowman, H. B. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.12.011 · Cited by 165
Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Steiner, M., & Neri, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0483 · Cited by 157
MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia
Benderra, Z., Faussat, A. M., Sayada, L., Perrot, J., Tang, R., Chaoui, D., Morjani, H., Marzac, C., Marie, J., & Legrand, O. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1895 · Cited by 154
Drug‐conjugated antibodies for the treatment of cancer
Lambert, J. M. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12044 · Cited by 153
Naito, K., Takeshita, A., Shigeno, K., Nakamura, S., Fujisawa, S., Shinjo, K., Yoshida, H., Ohnishi, K., Mori, M., Terakawa, S., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401851 · Cited by 153
Yin, G., Garces, E. D., Yang, J., Zhang, J., Tran, C., Steiner, A. R., Roos, C. M., Bajad, S. U., Hudak, S. A., Penta, K., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19202 · Cited by 151
Pharmacokinetic Considerations for Antibody Drug Conjugates
Lin, K., & Tibbitts, J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0800-y · Cited by 144
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 141
DiJoseph, J. F., Dougher, M. M., Kalyandrug, L. B., Armellino, D. C., Boghaert, E. R., Hamann, P. R., Moran, J. K., & Damle, N. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1905 · Cited by 140
Walter, R. B., Raden, B. W., Hong, T. C., Flowers, D. A., Bernstein, I. D., & Linenberger, M. L. (2003) · Blood · doi:10.1182/blood-2003-02-0396 · Cited by 135
Acquired resistance to drugs targeting receptor tyrosine kinases
Rosenzweig, S. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.025 · Cited by 129
Biological impediments to monoclonal antibody–based cancer immunotherapy
Christiansen, J., & Rajasekaran, A. K. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1493.3.11 · Cited by 125
Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer
Ford, C. H. J., Newman, C. E., Johnson, J. R., et al. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.4 · Cited by 118
Gorovits, B., & Krinos‐Fiorotti, C. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1369-3 · Cited by 116
Wang, X., Ma, D., Olson, W. C., & Heston, W. D. W. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0191 · Cited by 116
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
Law, C., Cerveny, C. G., Gordon, K. A., Klussman, K., Mixan, B. J., Chace, D. F., Meyer, D. L., Doronina, S. O., Siegall, C. B., Francisco, J. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1028 · Cited by 116
Smith, L. M., Nesterova, A., Alley, S. C., Torgov, M. Y., & Carter, P. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0026 · Cited by 108
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
Ackerman, M. E., Pawlowski, D., & Wittrup, K. D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0067 · Cited by 107
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Gerber, H., Koehn, F. E., & Abraham, R. T. (2013) · Natural Product Reports · doi:10.1039/c3np20113a · Cited by 102
Schmidt, M. M., Thurber, G. M., & Wittrup, K. D. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0518-1 · Cited by 100
Site specific protein labeling by enzymatic posttranslational modification
Sünbül, M., & Yin, J. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b908687k · Cited by 95
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
McDonagh, C. F., Kim, K. M., Turcott, E., Brown, L. L., Westendorf, L., Feist, T., Sussman, D. R., Stone, I. J., Anderson, M. E., Miyamoto, J. B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0295 · Cited by 95
Investigational antibody drug conjugates for solid tumors
Sapra, P., Hooper, A. T., O’Donnell, C. J., & Gerber, H. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.582866 · Cited by 92
Conjugation Site Heterogeneity Causes Variable Electrostatic Properties in Fc Conjugates
Boylan, N. J., Zhou, W., Proos, R. J., Tolbert, T. J., Wolfe, J. L., & Laurence, J. S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4000564 · Cited by 85
Site-specific Conjugation on Serine → Cysteine Variant Monoclonal Antibodies
Stimmel, J. B., Merrill, B. M., Kuyper, L. F., Moxham, C. P., Hutchins, J. T., Fling, M. E., & Kull, F. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001672200 · Cited by 78
A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis
Kadara, H. N., Behrens, C., Yuan, P., Solis, L. M., Liu, D., Gu, X., Minna, J. D., Lee, J. J., Kim, E., Hong, W.-K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2703 · Cited by 75
Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents
Jeffrey, S. C., Brabander, J. K. D., Miyamoto, J. B., & Senter, P. D. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100039h · Cited by 73
Goldmacher, V. S., & Kovtun, Y. (2011) · Therapeutic Delivery · doi:10.4155/tde.10.98 · Cited by 73
Palumbo, A., Hauler, F., Dziunycz, P., Schwager, K., Soltermann, A., Pretto, F., Alonso, C., Hofbauer, G. F. L., Boyle, R. W., & Neri, D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.78 · Cited by 72
Investigational antibody-drug conjugates for hematological malignancies
Polson, A. G., Ho, W., & Ramakrishnan, V. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.539557 · Cited by 71
Bajjuri, K. M., Liu, Y., Liu, C., & Sinha, S. C. (2010) · ChemMedChem · doi:10.1002/cmdc.201000478 · Cited by 69
Petersen, B. H., Deherdt, S. V., Schneck, D. W., & Bumol, T. F. (1991) · PubMed · Cited by 66
Boghaert, E. R., Khandke, K. M., Sridharan, L., Dougher, M. M., DiJoseph, J. F., Kunz, A., Hamann, P. R., Moran, J. K., Chaudhary, I., & Damle, N. K. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0560-2 · Cited by 66
Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Shochat, D., & Mountain, A. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049794n · Cited by 60
Immunoradioactive agent against cancer.
GHOSE, T., Cerini, M. E. D., Carter, M., et al. (1967) · BMJ · doi:10.1136/bmj.1.5532.90 · Cited by 59
An Antibody–Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of Melanoma
Asundi, J., Reed, C., Arca, J., McCutcheon, K. M., Ferrando, R. E., Clark, S., Luis, E., Tien, J., Firestein, R., & Polakis, P. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2340 · Cited by 58
Madej, M. P., Coia, G., Williams, C. C., Caine, J. M., Pearce, L. A., Attwood, R. M., Bartone, N., Dolezal, O., Nisbet, R. M., Nuttall, S. D., et al. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.24407 · Cited by 56
Owen, S. C., Patel, N., Logie, J., Pan, G., Persson, H., Moffat, J., Sidhu, S. S., & Shoichet, M. S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.011 · Cited by 55
Tang, R., Cohen, S., Perrot, J., Faussat, A., Zuany‐Amorim, C., Marjanovic, Z., Morjani, H., Fava, F., Corre, E., Legrand, O., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-199 · Cited by 50
Janthur, W.-D., Cantoni, N., & Mamot, C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131216020 · Cited by 50
Safety of rituximab maintenance therapy in follicular lymphomas
Solal‐Céligny, P. (2006) · Leukemia Research · doi:10.1016/s0145-2126(06)80004-4 · Cited by 47
Chemoimmunoconjugates for the Treatment of Cancer
Pietersz, G. A., Rowland, A. J., Smyth, M. J., & McKenzie, I. F. C. (1994) · Advances in immunology · doi:10.1016/s0065-2776(08)60455-1 · Cited by 38
Yoshikawa, M., Mukai, Y., Okada, Y., Tsumori, Y., Tsunoda, S., Tsutsumi, Y. M., Aird, W. C., Yoshioka, Y., Okada, N., Doi, T., et al. (2013) · Blood · doi:10.1182/blood-2012-12-468363 · Cited by 37
Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF
Giroux, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.037 · Cited by 34
Lu, D., Sahasranaman, S., Zhang, Y., & Girish, S. (2013) · Bioanalysis · doi:10.4155/bio.13.76 · Cited by 22
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2018) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 786
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Metadata
- Authors
- Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 19
- Issue
- 7
- Pages
- 869-881
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2139343978
- Cited by
- 470
- References
- 106
- FWCI
- 25.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.